NCT04094610: A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

NCT04094610
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ALK, ROS, NTRK
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 4 Years to 12 Years (Child)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with unstable untreated CNS metastases – see trial for details
https://ClinicalTrials.gov/show/NCT04094610

Comments are closed.

Up ↑